The purpose of this study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) used cardiovascular and antidiabetic drugs. An additional aim was to investigate whether such co-medication differed according to gender, age and amount of antiobesity drugs used.
Data were retrieved from the Norwegian Prescription Database (NorPD). All patients who had an antiobesity drug (ATC code A08A) dispensed from a Norwegian pharmacy between January 2004 and December 2007 were included in the study.
During the 4-year study period 83,717 patients had antiobesity drugs dispensed. One in three patients using antiobesity drugs had at least on one occasion used a cardiovascular and/or an antidiabetic drug concomitantly. A significantly higher percentage of men used antihypertensives (40.4 vs. 27.2%, P
Notes
Cites: BMC Fam Pract. 2006;7:4316827937
Cites: Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):631-819415767
Cites: BMJ. 2006 Sep 23;333(7569):640-216990325
Cites: Tidsskr Nor Laegeforen. 2007 Jan 4;127(1):34-717205087
Cites: J Gen Intern Med. 2007 Jun;22(6):805-1017406952
Cites: BMJ. 2007 Dec 8;335(7631):1194-918006966
Cites: Br J Gen Pract. 2005 Oct;55(519):743-916212848
Cites: Int J Clin Pharmacol Ther. 2009 Feb;47(2):104-1019203566
Cites: Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):405-1116981229
Cites: Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-719667004